Quantitative Risk-Benefit Analysis of Probiotic Use for Irritable Bowel Syndrome and Inflammatory Bowel Disease.

about

Quantitative Risk-Benefit Analysis of Probiotic Use for Irritable Bowel Syndrome and Inflammatory Bowel Disease.

Item

http://www.wikidata.org/entity/Q38607318

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Quantitative Risk-Benefit Anal ...... nd Inflammatory Bowel Disease.

@en

type

Item

label

Quantitative Risk-Benefit Anal ...... nd Inflammatory Bowel Disease.

@en

prefLabel

Quantitative Risk-Benefit Anal ...... nd Inflammatory Bowel Disease.

@en

P1476

Quantitative Risk-Benefit Anal ...... nd Inflammatory Bowel Disease.

@en

P2093

William E Bennett

http://www.w3.org/2001/XMLSchema#string

P2860

Probiotics for treating acute infectious diarrhoea

Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis

Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections

Joint distribution approaches to simultaneously quantifying benefit and risk

A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention.

Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial.

Effect of probiotics on symptoms in korean adults with irritable bowel syndrome.

Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN)

Role of antispasmodics in the treatment of irritable bowel syndrome.

P2888

s40264-015-0349-x

P304

295-305

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40264-015-0349-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1047726400

http://www.w3.org/2001/XMLSchema#string

P698

26467550

http://www.w3.org/2001/XMLSchema#string

P921

probiotics

inflammatory bowel diseases